Critical Reviews in Oncology / Hematology
Volume 77, Issue 1 , Pages 30-47 , January 2011

Positron emission tomography and colorectal cancer

  • Michael Lin

      Affiliations

    • Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, Australia
    • University of New South Wales, Sydney, Australia
    • South Western Sydney Colorectal Tumour Group, Sydney South West Area Health Service, Sydney, Australia
    • Corresponding Author InformationCorresponding author at: Department of Nuclear Medicine and PET, 1 Elizabeth Drive, Liverpool Hospital, Liverpool, New South Wales 2170, Australia. Tel.: +61 2 9828 3515; fax: +61 2 9828 3529.
    • ,
  • Karen Wong

      Affiliations

    • University of New South Wales, Sydney, Australia
    • South Western Sydney Colorectal Tumour Group, Sydney South West Area Health Service, Sydney, Australia
    • Department of Radiation Oncology, Liverpool Hospital, Sydney, Australia
    • ,
  • Weng Leong Ng

      Affiliations

    • University of New South Wales, Sydney, Australia
    • South Western Sydney Colorectal Tumour Group, Sydney South West Area Health Service, Sydney, Australia
    • Department of Medical Oncology, Liverpool Hospital, Sydney, Australia
    • ,
  • Ivan Ho Shon

      Affiliations

    • Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, Australia
    • University of New South Wales, Sydney, Australia
    • ,
  • Matthew Morgan

      Affiliations

    • South Western Sydney Colorectal Tumour Group, Sydney South West Area Health Service, Sydney, Australia
    • Department of Colorectal Surgery, Bankstown Hospital, Sydney, Australia

,Accepted 30 April 2010.

References 

  1. Van Cutsem E, Oliveira J. Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2009;20(Suppl. 4):49–50
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225–249
  3. Lin M, Ho Shon I, Lin P. Positron emission tomography–current status and future challenges. Intern Med J. 2010;40:19–29
  4. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26:2155–2161
  5. Papathanassiou D, Bruna-Muraille C, Liehn J-C, Nguyen TD, Curé H. Positron Emission Tomography in oncology: Present and future of PET and PET/CT. Crit Rev Oncol Hematol. 2009;72:239–254
  6. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357–4368
  7. Cohade C, Osman M, Leal J, Wahl R. Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44:1797–1803
  8. Czernin J, Allen-Auerbach M, Schelbert H. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007;48:78S–88S
  9. Burt BM, Humm JL, Kooby DA, et al. Using positron emission tomography with [18F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia. 2001;3:189–195
  10. Veit-Haibach P, Kuehle CA, Beyer T, et al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA. 2006;296:2590–2600
  11. Nagata K, Ota Y, Okawa T, Endo S, Kudo SE. PET/CT colonography for the preoperative evaluation of the colon proximal to the obstructive colorectal cancer. Dis Colon Rectum. 2008;51(6):882–890
  12. Heriot A, Kumar D. Rectal cancer recurrence: factors and mechanisms. Colorectal Dis. 2000;2:126–137
  13. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet. 1986;328(8514):996–999
  14. Adam IJ, Mohamdee MO, Martin IG, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet. 1994;344(8924):707–711
  15. Chan KW, Boey J, Wong SK. A method of reporting radial invasion and surgical clearance of rectal carcinoma. Histopathology. 1985;9(12):1319–1327
  16. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333(7572):779
  17. Klessen C, Rogalla P, Taupitz M. Local staging of rectal cancer. The current role of MRI. Eur Radiol. 2007;17:379–389
  18. Bipat S, Glas AS, Slors FJM, Zwinderman AH, Bossuyt PMM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-a meta-analysis. Radiology. 2004;232:773–783
  19. Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology. 2003;227:371–377
  20. Gearhart SL, Frassica D, Rosen R, Choti M, Schulick R, Wahl R. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol. 2006;13:397–404
  21. Davey K, Heriot AG, Mackay J, et al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum. 2008;51:997–1003
  22. Heriot AG, Hicks RJ, Drummond EGP, et al. Does positron emission tomography change management in primary rectal cancer? A prospective assessment. Dis Colon Rectum. 2004;47:451–458
  23. Llamas-Elvira JM, Rodriguez-Fernandez A, Gutierrez-Sainz J, et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:859–867
  24. Akiyoshi T, Oya M, Fujimoto Y, et al. Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer. Colorectal Dis. 2009;11:464–469
  25. Eglinton T, Luck A, Bartholomeusz D, Varghese R, Lawrence M. Positron-emission tomography/computed tomography in the initial staging of primary rectal cancer. Colorectal Dis. 2010;12:667–673
  26. Furukawa H, Ikuma H, Seki A, et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut. 2006;55:1007–1011
  27. Tateishi U, Maeda T, Morimoto T, Miyake M, Arai Y, Kim EE. Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:1627–1634
  28. Nahas CSR, Akhurst T, Yeung H, et al. Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol. 2008;15(3):704–711
  29. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology. 1998;206:755–760
  30. Mukai M, Sadahiro S, Yasuda S, et al. Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep. 2000;7:85–87
  31. Kantorova I, Lipska L, Belohlavek O, Visokai V, Trubac M, Schneiderova M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003;44:1784–1788
  32. Monig SP, Baldus SE, Zirbes TK, et al. Lymph node size and metastatic infiltration in colon cancer. Ann Surg Oncol. 1999;6(6):579–581
  33. Park IJ, Kim HC, Yu CS, et al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol. 2006;32(9):941–947
  34. Galandiuk S, Wieand HS, Moertel CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet. 1992;174:27–32
  35. Salo JC, Paty PB, Guillem J, Minsky BD, Harrison LB, Cohen AM. Surgical salvage of recurrent rectal carcinoma after curative resection: a 10 year experience. Ann Surg Oncol. 1999;6:171–177
  36. Tepper JE, O’Connell M, Hollis D, Niedzwiecki D, Cooke E, Mayer RJ. Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol. 2003;21:3623–3628
  37. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–318
  38. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13(5):668–676
  39. Steele G, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol. 1991;9:1105–1112
  40. Lejeune C, Bismuth MJ, Conroy T, et al. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med. 2005;46:2020–2028
  41. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177–1189
  42. Meta J, Seltzer M, Schiepers C, et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med. 2001;42:586–590
  43. Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med. 2002;43:492–499
  44. Scott AM, Gunawardana DH, Kelley B, et al. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med. 2008;49:1451–1457
  45. National Comprehensive Cancer Network-Clinical Practice Guidelines in Oncology: Colon Cancer, v.1.2009, available at www.nccn.org.
  46. Australian Cancer Network Colorectal Cancer Guidelines Revision Committee . Guidelines for the prevention, early detection and management of colorectal cancer. Sydney: The Cancer Council Australia and Australian Cancer Network; 2005;
  47. Yonekura Y, Benua RS, Brill AB, et al. Increased accumulation of 2-deoxy-2-[18F]Fluoro-d-glucose in liver metastases from colon carcinoma. J Nucl Med. 1982;23:1133–1137
  48. Wiering B, Krabbe PFM, Jager GJ, Oyen WJG, Ruers TJM. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer. 2005;104:2658–2670
  49. Bipat S, van Leeuwen MS, Comans EFI, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis—meta-analysis. Radiology. 2005;237:123–131
  50. Kong G, Jackson C, Koh DM, et al. The use of (18)F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging. 2008;35:1323–1329
  51. Schussler-Fiorenza CM, Mahvi DM, Niederhuber J, Rikkers LF, Weber SM. Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. J Gastrointest Surg. 2004;8:150–158
  52. Coenegrachts K, De Geeter F, ter Beek L, et al. Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases. Eur Radiol. 2009;19:370–379
  53. Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg. 2001;233:293–299
  54. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438–447
  55. Pawlik TM, Assumpcao L, Vossen JA, et al. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. Ann Surg Oncol. 2009;16:371–378
  56. Ruers TJM, Wiering B, van der Sijp JRM, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with 18F-FDG PET: a randomized study. J Nucl Med. 2009;50:1036–1041
  57. Finkelstein SE, Fernandez FG, Dehdashti F, et al. Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET. J Hepatobiliary Pancreat Surg. 2008;15:483–487
  58. Riedl CC, Akhurst T, Larson S, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48:771–775
  59. de Geus-Oei LF, Wiering B, Krabbe PF, Ruers TJM, Punt CJA, Oyen WJG. FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol. 2006;17:1650–1655
  60. Scheer MGW, Stollman TH, Vogel WV, Boerman OC, Oyen WJG, Ruers TJM. Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med. 2008;49:887–891
  61. Beets G, Penninckx F, Schiepers C, et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg. 1994;81:1666–1670
  62. Strauss LG, Corius JH, Schlag P, et al. Recurrence of colorectal tumours: PET evaluation. Radiology. 1989;170:329–332
  63. Ito K, Kato T, Tadokoro M, et al. Recurrent rectal cancer and scar differentiation with PET and MR imaging. Radiology. 1992;182:549–552
  64. Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum. 2000;43:759–767
  65. Flamen P, Stroobants S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d-glucose in recurrent colorectal cancer. J Clin Oncol. 1999;17:894–901
  66. Lonneux M, Reffad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2002;29:915–921
  67. Even-Sapir E, Parag Y, Lerman H, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology. 2004;232:815–822
  68. Votrubova J, Belohlavek O, Jaruskova M, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2006;33:779–784
  69. Kitajima K, Murakami K, Yamasaki E, et al. Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging. 2009;36:1388–1396
  70. Minton JP, Hoehn JL, Gerber DM, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer. 1985;55:1284–1290
  71. Ruhlmann J, Schomburg A, Bender H, et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum. 1997;40:1195–1204
  72. Zervos EE, Badgwell BD, Burak WE, Arnold MW, Martin EW. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery. 2001;130:636–643
  73. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998;227:319–323
  74. Liu FY, Chen JS, Changchien CR, et al. Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels. Dis Colon Rectum. 2005;48:1900–1912
  75. Choi MY, Lee KM, Chung JK, et al. Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer. Ann Nucl Med. 2005;19(2):123–129
  76. Sarikaya I, Bloomston M, Povoski SP, et al. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol. 2007;5:64
  77. Tanaka T, Kawai Y, Kanai M, Taki Y, Nakamoto Y, Takabayashi A. Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer. Am J Surg. 2002;184:433–436
  78. Dromain C, Leboulleux S, Auperin A, et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging. 2007;33:87–93
  79. De Gaetano AM, Calcagni ML, Rufini V, Valenza V, Giordano A, Bonomo L. Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. Abdom Imaging. 2009;34(3):391–402
  80. Dirisamer A, Schima W, Heinisch M, et al. Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT. Eur J Radiol. 2009;69:536–541
  81. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247
  82. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl. 1):122S–150S
  83. Guillem JG, Puig-La Calle J, Akhurst T, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluordeoxyglucose positron emission tomography. Dis Colon Rectum. 2000;43:18–24
  84. Amthauer H, Denecke T, Rau B, et al. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging. 2004;31(6):811–819
  85. Denecke T, Rau B, Hoffmann KT, et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?. Eur Radiol. 2005;15:1658–1666
  86. Melton GB, Lavely WC, Jacene HA, et al. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg. 2007;11:961–969
  87. Vliegen RF, Beets-Tan RG, Vanhauten B, et al. Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?. Strahlenther Onkol. 2008;184:457–464
  88. Konski A, Li T, Sigurdson E, et al. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys. 2009;74(1):55–59
  89. Cascini GL, Avallone A, Delrio P, et al. 18 F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med. 2006;47:1241–1248
  90. Capirci C, Rubello D, Chierichetti F, et al. Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. Am J Roentgenol. 2006;187:202–208
  91. Kalff V, Duong C, Drummond EG, Matthews JP, Hicks RJ. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med. 2006;47:14–22
  92. Kalff V, Ware R, Heriot A, Chao M, Drummond E, Hicks RJ. Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy. Int J Radiation Oncology Biol Phys. 2009;74(1):60–66
  93. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how?. Br J Cancer. 2009;100:1704–1719
  94. Goshen E, Davidson T, Zwas ST, Aderka D. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat. 2006;5:37–43
  95. Strauss LG, Koczan D, Klippel S, et al. Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors. J Nucl Med. 2008;49:1238–1244
  96. Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol. 2005;23:8713–8716
  97. Lubezky N, Metser U, Geva R, et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg. 2007;11:472–478
  98. Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg. 2007;11:1112–1119
  99. Adie S, Yip C, Chu F, Morris DL. Resection of liver metastases from colorectal cancer: does preoperative chemotherapy affect the accuracy of PET in preoperative planning?. ANZ J Surg. 2009;79:358–361
  100. Takahashi S, Kuroki Y, Nasu K, et al. Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy. Anticancer Res. 2006;26:4705–4711
  101. Small RM, Lubezky N, Shmueli E, et al. Response to chemotherapy predicts survival following resection of hepatic colorectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol. 2009;99:93–98
  102. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700–708
  103. Bender H, Bangard N, Metten N, et al. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. Hybridoma. 1999;18:87–91
  104. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med. 2004;45:1480–1487
  105. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med. 2003;47:8–13
  106. de Geus-Oei LF, van Laarhoven HW, Visser EP, et al. Chemotherapy response evaluation with FDG PET in patients with colorectal cancer. Ann Oncol. 2007;19:348–352
  107. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–1782
  108. Bystrom P, Berglund A, Garske U, et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol. 2009;20:1057–1062
  109. Langenhoff BS, Oyen WJ, Jager GJ, et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol. 2002;20:4453–4458
  110. Donckier V, Van Laethem JL, Goldman S, et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol. 2003;84:215–223
  111. Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med. 2003;28:192–197
  112. Joosten J, Jager G, Oyen W, Wobbes T, Ruers T. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol. 2005;31:1152–1159
  113. Blokhuis TJ, van der Schaaf MC, van den Tol MP, Comans EFI, Manoliu RA, van der Sijp JR. Results of radio frequency ablation of primary and secondary liver tumors: long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning. Scand J Gastroenterol (Suppl). 2004;241:93–97
  114. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol. 2006;16:80–87
  115. Travaini L, Trifiro G, Ravasi L, et al. Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging. 2008;35:1316–1322
  116. Barker DW, Zagoria RJ, Morton KA, Kavanagh PV, Shen P. Evaluation of liver metastases after radiofrequency ablation: Utility of 18F-FDG PET and PET/CT. Am J Roentgenol. 2005;184(4):1096–1102
  117. Kuehl H, Antoch G, Stergar H, et al. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: Initial results. Eur J Radiol. 2008;67:362–371
  118. Khandani AH, Calvo BF, O’Neil BH, Jorgenson J, Mauro MA. A pilot study of early 18F-FDG PET to evaluate the effectiveness of radiofrequency ablation of liver metastases. Am J Roentgenol. 2007;189:1199–1202
  119. Denecke T, Steffen I, Hildebrandt B, et al. Assessment of local control after laser-induced thermotherapy of liver metastases from colorectal cancer: contribution of FDG-PET in patients with clinical suspicion of progressive disease. Acta Radiol. 2007;48:821–830
  120. Avril N. 18F-FDG PET after radiofrequency ablation: is timing everything?. J Nucl Med. 2006;47:1235–1237
  121. Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging. 2002;29:815–820
  122. Popperl G, Helmberger T, Munzing W, Schmind R, Jacobs TF, Tasch K. Selective internal radiation therapy with SIR-spheres in patients with nonresectable liver tumours. Cancer Biother Radiopharm. 2005;20:200–208
  123. Lin M, Shon IH, Wilson R, D’Amours SK, Schlaphoff G, Lin P. Treatment response in liver metastases following 90Y SIR-spheres: an evaluation with PET. Hepatogastroenterology. 2007;54:910–912
  124. Biernert M, McCook B, Carr BI, et al. 90Y microsphere treatment of unresectable liver metastases: changes in the FDG uptake and tumor size on PET–CT. Eur J Nucl Med Mol Imaging. 2005;32:778–787
  125. Szyszko T, Al-Nahhas A, Canelo R, et al. Assessment of response to treatment of unresectable liver tumours with Y90 microspheres: Value of FDG–PET versus computed tomography. Nucl Med Commun. 2007;28:15–20
  126. Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med. 2004;45:1892–1897
  127. Wong CY, Qing F, Savin M, et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol. 2005;16:1101–1106
  128. Flamen P, Vanderlinden B, Delatte P, et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys Med Biol. 2008;53:6591–6603
  129. Gregoire V, Haustermans K, Geets X, Roels S, Lonneux M. PET-based treatment planning in radiotherapy: a new standard?. J Nucl Med. 2007;48:68–77S
  130. Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated Positron Emission and Computer Tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys. 2003;57:853–863
  131. Ciernik IF, Huser M, Burger C, Davis JB, Szekely G. Automated functional image-guided radiation treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:893–900
  132. Patel DA, Chang ST, Goodman KA, et al. Impact of integrated PET/CT on variability of target volume delineation in rectal cancer. Technol Cancer Res Treat. 2007;6:31–36
  133. Anderson C, Koshy M, Staley C, et al. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys. 2007;69:155–162
  134. Bassi MC, Turri L, Sacchetti G, et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:1423–1426
  135. Paskeviciute B, Bölling T, Brinkmann M, et al. Impact of 18F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer. Strahlenther Onkol. 2009;185:260–265
  136. Roels S, Slagmolen P, Nuyts J, et al. Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG?. Acta Oncol. 2008;47:1237–1248
  137. Roels S, Slagmolen P, Nuyts J, et al. Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls. Int J Radiat Oncol Biol Phys. 2009;75:782–790
  138. Li Destri G, Di Cataldo A, Puleo S. Colorectal cancer follow-up: useful or useless?. Surg Oncol. 2006;15:1–12
  139. Goldberg RM, Fleming TR, Tangen CM, et al. Surgery for recurrent colon cancer:strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med. 1998;129:27–35
  140. Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up?. J Nucl Med. 2009;50:24–29
  141. Brooks RA, Rader JS, Dehdashti F, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol. 2009;112:104–109
  142. Selvaggi F, Cuocolo A, Sciaudone G, Maurea S, Giuliani A, Mainolfi C. FGD-PET in the follow-up of recurrent colorectal cancer. Colorectal Dis. 2003;5:496–500
  143. Sobhani I, Tiret E, Lebtahi R, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer. 2008;98(5):875–880
  144. Lieberman D. Colon cancer screening and surveillance controversies. Curr Opin Gastroenterol. 2009;25(5):422–427
  145. Yasuda S, Shohtsu A. Cancer screening with whole-body 18F-fluorodeoxyglucose positron-emission tomography. Lancet. 1997;350:1819
  146. Yasuda S, Fujii H, Nakahara T, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med. 2001;42:989–992
  147. Kojima S, Zhou B, Teramukai S, et al. Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: The Nishidai clinic study. Eur J Cancer. 2007;43:1842–1848
  148. Terauchi T, Murano T, Daisaki H, et al. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography: a preliminary report. Ann Nucl Med. 2008;22:379–385
  149. Minamimoto R, Senda M, Uno K, et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med. 2007;21:481–491
  150. Nishizawa S, Kojima S, Teramukai S, et al. Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]Fluorodeoxyglucose Positron Emission Tomography in a healthy population: a preliminary report. J Clin Oncol. 2009;27:1767–1773
  151. Beatty JS, Williams HT, Aldridge BA, et al. Incidental PET/CT findings in the cancer patient: how should they be managed?. Surgery. 2009;146(2):274–281
  152. Hillman BJ. Screening for cancer with high technology imaging tests. J Clin Oncol. 2009;27:1740–1741
  153. Kamel EM, Thumshirn M, Truninger K, et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med. 2004;45:1804–1810
  154. Agress H, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology. 2004;230:417–422
  155. Israel O, Yefremov N, Bar-Shalom R, et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med. 2005;46:758–762
  156. Even-Sapir E, Lerman H, Gutman M, et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging. 2006;33:541–552
  157. Van Kouwen MCA, Nagengast FM, Jansen JBMJ, Oyen WJG, Drenth JPH. 2-(18F)-fluoro-2-deoxy-d-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol. 2005;23:3713–3717
  158. Gutman F, Alberini J-L, Wartski M, et al. Incidental colonic focal lesions detected by FDG PET/CT. Am J Roentgenol. 2005;185:495–500
  159. Hemandas AK, Robson NK, Hickish T, Talbot RW. Colorectal tubulovillous adenomas identified on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scans. Colorectal Dis. 2008;10(4):386–389
  160. Lee ST, Tan T, Poon AMT, et al. Role of low-dose, noncontrast computed tomography from integrated positron emission tomography/computed tomography in evaluating incidental 2-deoxy-2-[F-18]fluoro-d-glucose-avid colon lesions. Mol Imaging Biol. 2008;10(1):48–53
  161. Lee JC, Hartnett GF, Hughes BGM, Ravi Kumar AS. The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT. Nucl Med Commun. 2009;30:333–337
  162. Schlemmer HPW, Pichler BJ, Schmand M, et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology. 2008;248(3):1028–1035
  163. Giesel FL, Mehndiratta A, Locklin J, et al. Exp Oncol. 2009;31:106–114
  164. Cherry SR. Multimodality imaging: beyond PET/CT and SPECT/CT. Semin Nucl Med. 2009;39:348–353
  165. Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878–883
  166. Wieder H, Ott K, Zimmermann F, et al. PET imaging with [11C]methyl-l-methionine for therapy monitoring in patients with rectal cancer. Eur J Nucl Med. 2002;29:789–796
  167. Dietz DW, Dehdashti F, Grigsby PW, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Col Rectum. 2008;51:1641–1648

PII: S1040-8428(10)00119-8

doi: 10.1016/j.critrevonc.2010.04.011

Critical Reviews in Oncology / Hematology
Volume 77, Issue 1 , Pages 30-47 , January 2011

Article Tools

* Image Usage & Resolution